Third Pole Therapeutics said it has successfully completed an early feasibility study of its portable inhaled nitric oxide (iNO)…
Articles by Steve Bryson, PhD
Note: This story was updated Jan. 30, 2024, to correct the approved indications of available treprostinil formulations. The U.S.
A protein known as MCJ might be a target of treatments needed to preserve heart function in people with…
Pulmonary arterial dilatation — the abnormal widening of the main pulmonary artery leading from the heart — was a common feature…
An early feasibility study evaluating Third Pole Therapeutics‘ eNOfit — a miniaturized, portable inhaled nitric oxide (iNO) delivery system…
Lower levels of apolipoprotein A-I (ApoA-I), a component of high-density lipoprotein (HDL), or “good cholesterol,” is a significant predictor of…
The activation of clinical sites for a global Phase 3 study to evaluate Gossamer Bio’s inhaled seralutinib (GB002), an…
Four proteins related to a pro-inflammatory signaling molecule called TNF-alpha may serve as biomarkers to predict mortality in adults with…
Researchers have identified three proteins — NID1, C1QTNF1, and CRTAC1 — in the bloodstream of people with pulmonary hypertension…
The presence of pulmonary hypertension (PH) didn’t increase mortality after a heart transplant, according to a new study. The…
AI Therapeutics has begun dosing in a clinical trial testing inhaled LAM-001, a potential disease-modifying therapy for pulmonary…
Older age and high blood pressure in the pulmonary arteries raise the risk of complications with balloon pulmonary angioplasty (BPA),…